DeVita VT Jr and Chu E: A history of cancer chemotherapy. Cancer Res. 68:8643–8653. 2008. View Article : Google Scholar : PubMed/NCBI

Sawyers C: Targeted cancer therapy. Nature. 18:294–297. 2004. View Article : Google Scholar

Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S: The protein kinase complement of the human genome. Science. 298:1912–1934. 2002. View Article : Google Scholar : PubMed/NCBI

Prenzel N, Fischer OM, Steit S, Hart S and Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 8:11–31. 2001. View Article : Google Scholar : PubMed/NCBI

Slichenmyer WJ and Fry DW: Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol. 28(5 Suppl 16): 67–79. 2001. View Article : Google Scholar : PubMed/NCBI

Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P and Jones A: Cardotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomized controlled trails. BMC Cancer. 10:3372010. View Article : Google Scholar : PubMed/NCBI

van Dalen EC, Michiels EM, Caron HN and Kremer LC: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. CDOO50062010.

Ewer MS and Ewer SM: Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat Rev Cariol. 7:564–575. 2010. View Article : Google Scholar

Billingham ME, Mason JW, Bristow MR and Daniels JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 62:865–872. 1978.PubMed/NCBI

Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME and Harrison DC: Early anthracyline cardiotoxicity. Am J Med. 65:823–832. 1978. View Article : Google Scholar : PubMed/NCBI

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification for the HER-2/new oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI

Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch and Wrba F: HER 2/new protein expression in colorectal cancer. BMC Cancer. 6:1232006. View Article : Google Scholar : PubMed/NCBI

Latif Z, Watters AD, Bartlett JM, Underwood MA and Aitchison M: Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int. 89:5–9. 2002. View Article : Google Scholar : PubMed/NCBI

Jelovac D and Emens LA: HER2-directed therapy for metastatic breast cancer. Oncology (Williston Park). 27:166–175. 2013.PubMed/NCBI

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S and Dessanai MA: Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 28:3910–3916. 2010. View Article : Google Scholar : PubMed/NCBI

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F and Desai J: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 370:2011–2019. 2007. View Article : Google Scholar : PubMed/NCBI

Shaikh AY and Shih JA: Chemotherapy-induced cardiotoxicity. Curr Heart Fail Rep. 9:117–27. 2012. View Article : Google Scholar : PubMed/NCBI

Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ and Keefe D: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 20:1215–1221. 2002. View Article : Google Scholar : PubMed/NCBI

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J and Pegram M: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–92. 2001. View Article : Google Scholar : PubMed/NCBI

Guarneri V, Lenihan DJ, Velaro V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN and Esteva FJ: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson cancer center experience. J Clin Oncol. 24:4107–4115. 2006. View Article : Google Scholar : PubMed/NCBI

Ewer MS, Vooletich MT, Durand JB, Wood ML, Davis JR, Valero V and Lenihan DJ: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol. 23:7820–7826. 2005. View Article : Google Scholar : PubMed/NCBI

Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S and Kaufman P: Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol. 27:2638–2644. 2009. View Article : Google Scholar : PubMed/NCBI

Garratt AN, Ozcelik C and Birchmeier C: ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med. 13:80–86. 2003. View Article : Google Scholar : PubMed/NCBI

Negro A, Brar BK and Lee KF: Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res. 59:1–12. 2004. View Article : Google Scholar : PubMed/NCBI

Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R and Condorelli G: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 8:459–465. 2002. View Article : Google Scholar : PubMed/NCBI

Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hübner N, Chien KR, Birchmeier C and Garratt AN: Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Pro Natl Acad Sci USA. 99:8880–8885. 2002. View Article : Google Scholar

Burris HA III, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, et al: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 23:5305–5313. 2005. View Article : Google Scholar : PubMed/NCBI

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jaqiello-Gruszfeld A, Crown J, Chan A and Kaufman B: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355:2733–2743. 2006. View Article : Google Scholar : PubMed/NCBI

Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, et al: Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of peruzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 28:1131–1137. 2010. View Article : Google Scholar : PubMed/NCBI

Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E and Ewer MS: Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 83:679–686. 2008. View Article : Google Scholar : PubMed/NCBI

Fedele C, Riccio G, Malara AE, D'Alessio G and De Lorenzo C: Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat. 134:595–602. 2012. View Article : Google Scholar : PubMed/NCBI

Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 6:443–446. 2000. View Article : Google Scholar : PubMed/NCBI

Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C and Gibelli N: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HERS2. Clin Cancer Res. 10:5650–5655. 2004. View Article : Google Scholar : PubMed/NCBI

Van Cutsem E, Lambrechts D, Prenen H, Jain RK and Carmeliet P: Lessons from the adjuvant bevacizumab trial on colon cancer: What next? J Clin Oncol. 29:1–4. 2011. View Article : Google Scholar : PubMed/NCBI

Jardim DL, de Gagliato DM, Ribeiro KB, Shimada AK and Katz A: Bevacizumab as first-line therapy in advanced non-small-cell-lung cancer: A Brazillian center experience. Drugs R D. 12:207–216. 2012. View Article : Google Scholar : PubMed/NCBI

Rini BI: Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions. Clin Cancer Res. 13:1098–1106. 2007. View Article : Google Scholar : PubMed/NCBI

Scappacticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Kolmangren E, Wang J and Hurwitz H: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 99:1232–1239. 2007. View Article : Google Scholar : PubMed/NCBI

Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 23:3502–3508. 2005. View Article : Google Scholar : PubMed/NCBI

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD and Sing AP: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 23:792–799. 2005. View Article : Google Scholar : PubMed/NCBI

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III, Gaudreault J, Damico LA, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-lung cancer. J Clin Oncol. 22:2184–2191. 2004. View Article : Google Scholar : PubMed/NCBI

Hurwitz H and Saini S: Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events. Semin Oncol. 33(5 Suppl 10): S26–S34. 2006. View Article : Google Scholar : PubMed/NCBI

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S and Holmgren E: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI

Pande A, Lombardo J, Spangenthal E and Javle M: Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab. Anticancer Res. 27:3465–3470. 2007.PubMed/NCBI

Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA and Ewer MS: Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis and management. Circulation. 109:3122–3131. 2004. View Article : Google Scholar : PubMed/NCBI

D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H and Maki RG: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 23:7135–7142. 2005. View Article : Google Scholar : PubMed/NCBI

Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M and Chen H: Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 10:3577–3585. 2004. View Article : Google Scholar : PubMed/NCBI

Nalluri SR, Chu D, Keresztes R, Zhu X and Wu S: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA. 300:2277–2285. 2008. View Article : Google Scholar : PubMed/NCBI

Laitinen M, Zachary I, Breier G, Pakkanen T, Häkinen T, Luoma J, Abedi H, Risau W, Soma M, Laakso M, et al: VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther. 8:1737–1744. 1997. View Article : Google Scholar : PubMed/NCBI

Levy BI, Ambrosio G, Pries AR and Struijker-Boudier HA: Microcirculation in hypertension: A new target for treatment? Circulation. 104:735–740. 2001. View Article : Google Scholar : PubMed/NCBI

Hesser BA, Liang XH, Camenisch G, Yang S, Lewin DA, Scheller R, Ferrara N and Gerber HP: Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood. 104:149–158. 2004. View Article : Google Scholar : PubMed/NCBI

Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM and Hoekman K: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 22:1500–1505. 2002. View Article : Google Scholar : PubMed/NCBI

Whittle BJ, Moncada S and Vane JR: Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 16:373–388. 1978. View Article : Google Scholar : PubMed/NCBI

Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS and Walsh K: Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 47:887–893. 2006. View Article : Google Scholar : PubMed/NCBI

Cheng H and Force T: Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cariovasc Dis. 53:114–120. 2010. View Article : Google Scholar

Cheng H and Force T: Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 106:21–34. 2010. View Article : Google Scholar : PubMed/NCBI

Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH and Force T: Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2:15–25. 2009. View Article : Google Scholar : PubMed/NCBI

Kerkela R, Grazette L, Yacobi R, Illiescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S and Clubb FJ: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 12:908–16. 2006. View Article : Google Scholar : PubMed/NCBI

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C and Bleickardt E: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 354:2531–2541. 2006. View Article : Google Scholar : PubMed/NCBI

Deming PB, Schafer ZT, Tashker JS, Potts MB, Deshmukh M and Kornbluth S: Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol. 24:10289–10299. 2004. View Article : Google Scholar : PubMed/NCBI

Beininger M, Buchdunger E and Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 105:2640–2653. 2005. View Article : Google Scholar : PubMed/NCBI

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK and Wood R: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 8:935–942. 2002.PubMed/NCBI

Atallah E, Durand JB, Kantarjian H and Cortes J: Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 110:1233–1237. 2007. View Article : Google Scholar : PubMed/NCBI

Hatfield A, Owen S and Pilot PR: In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med. 13:13; author reply 15–16. 2007. View Article : Google Scholar

Rosti G, Martinelli G and Baccarani M: In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med. 13:15; author reply 15–16. 2007. View Article : Google Scholar

Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G and Pogliani E: In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med. 13:13–14; author reply 15–16. 2007. View Article : Google Scholar : PubMed/NCBI

Atallah E, Kantarjian H and Cortes J: In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med. 13:14; author reply 15–16. 2007. View Article : Google Scholar

Fernández A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W and Lopez-Berestein G: Rational drug redesign to overcome drug resistance in cancer therapy: Imatinib moving target. Cancer Res. 67:4028–4033. 2007. View Article : Google Scholar : PubMed/NCBI

Demetri GB: Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest. 117:3650–3653. 2007. View Article : Google Scholar : PubMed/NCBI

Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, Yasuzawa-Amano S, Trofimova I, Siggins RW and Lecapitaine N: Human cardiac stem cells. Proc Natl Acad Sci USA. 104:14068–14073. 2007. View Article : Google Scholar : PubMed/NCBI

Ghoreschi K, Laurence A and O'Shea JJ: Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat Immunol. 10:356–360. 2009. View Article : Google Scholar : PubMed/NCBI

U.S. Food Drug Administration FDA approves new treatment for gastrointestinal and kidney cancer. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108583.htmAccessed. January 26–2006

Young E, Miele L, Tucker KB, Huang M, Wells J and Gu JW: SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. Cancer Biol Ther. 10:703–711. 2010. View Article : Google Scholar : PubMed/NCBI

Xin H, Zhang C, Herrmann A, Du Y, Figlin R and Yu H: Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cell. Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI

Pal SK, Figlin RA and Yu H: Deciphering the anticancer mechanisms of sunitinib. Cancer Biol Ther. 10:712–714. 2010. View Article : Google Scholar : PubMed/NCBI

Telli ML, Witteles RM, Fisher GA and Srinivas S: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 19:1613–1618. 2008. View Article : Google Scholar : PubMed/NCBI

Motzer RJ, Hutson TE, Tomczk P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C and Kim ST: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomized controlled trial. Lancet. 368:1329–1338. 2006. View Article : Google Scholar : PubMed/NCBI

Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S, Bramwell O, Wong SC and Hong MK: Platelet-derived growth factor-AB limits the extent of mycocardial infarction in a rat model: Feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation. 105:608–613. 2002. View Article : Google Scholar : PubMed/NCBI

Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, Reddy AK, Coombes KR, Daher IN, Pati S, et al: Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest. 120:472–484. 2010. View Article : Google Scholar : PubMed/NCBI

Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS and Motzer RJ: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 103:763–773. 2011. View Article : Google Scholar : PubMed/NCBI

Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF and Wijeysundera DN: American College of Cardiology; American Heart Association: 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 64:e77–e137. 2014. View Article : Google Scholar : PubMed/NCBI